JACC-Heart Failure

Article	Citations
Complete Hemodynamic Profiling With Pulmonary Artery Catheters in Cardiogenic Shock Is Associated With Lower In-Hospital Mortality	169
Advanced Heart Failure	154
A Standardized and Comprehensive Approach to the Management of Cardiogenic Shock	137
Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis	131
Use of Cardiopulmonary Stress Testing for Patients With Unexplained Dyspnea Post–Coronavirus Disease	123
A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction	119
Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF	119
Hemodynamic and Functional Impact of Epicardial Adipose Tissue in Heart Failure With Preserved Ejection Fraction	108
COVID-19 Illness and Heart Failure	100
N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes	86
Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19	86
Reassessing Recipient Mortality Under the New Heart Allocation System	80
Considerations for Heart Failure Care During the COVID-19 Pandemic	75
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan	75
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists	75
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction	74
Sacubitril/Valsartan	66
COVID-19 in Heart Transplant Recipients	66
Application of Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction to the Community	66
Changes in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy	64
Clinical Role of CA125 in Worsening Heart Failure	59
Advanced Heart Failure Epidemiology and Outcomes	58
Care Gaps in Adherence to Heart Failure Guidelines	56
Heart Failure Drug Treatment—Inertia, Titration, and Discontinuation	55
Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy	55

Biomarker-Based Risk Prediction of Incident Heart Failure in Pre-Diabetes and Diabetes	54
Differential Pathophysiological Mechanisms in Heart Failure With a Reduced or Preserved Ejection Fraction in Diabetes	52
Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause	51
End-Stage Heart Failure With COVID-19	51
Natriuretic Peptides as Inclusion Criteria in Clinical Trials	51
Heart Transplantation	51
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure	49
Hemocompatibility-Related Adverse Events and Survival on Venoarterial Extracorporeal Life Support	48
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction	47
Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF	47
Epicardial Adipose Tissue and Invasive Hemodynamics in Heart Failure With Preserved Ejection Fraction	47
Impaired Exercise Tolerance in Heart Failure With Preserved Ejection Fraction	47
Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF	45
Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients	44
Health Literacy and Outcomes Among Patients With Heart Failure	44
Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction	43
A Machine Learning Approach to Management of Heart Failure Populations	42
Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF	41
Acute Kidney Function Declines in the Context of Decongestion in Acute Decompensated Heart Failure	40
Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation	40
Renal Compression in Heart Failure	39
A Pragmatic Approach to Weaning Temporary Mechanical Circulatory Support	39
The Impact of Patients With Cardiac Amyloidosis in HFpEF Trials	38
Splanchnic Nerve Block for Chronic Heart Failure	38
Differential Associations of Chronic Inflammatory Diseases With Incident Heart Failure	37
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction	36
Use of the Win Ratio in Cardiovascular Trials	35
Unexpectedly Low Natriuretic Peptide Levels in Patients With Heart Failure	34
Sex Differences in Patients Receiving Left Ventricular Assist Devices for End-Stage Heart Failure	34
Prognostic Implications of Staging Right Heart Failure in Patients With Significant Secondary Tricuspid Regurgitation	33
Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With Heart Failure	33
Drug Layering in Heart Failure	31
Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines	31
Rehabilitation Intervention in Older Patients With Acute Heart Failure With Preserved Versus Reduced Ejection Fraction	30
ECMO as a Bridge to Left Ventricular Assist Device or Heart Transplantation	29
Utility of Restricted Mean Survival Time Analysis for Heart Failure Clinical Trial Evaluation and Interpretation	29
Lung Ultrasound–Guided Emergency Department Management of Acute Heart Failure (BLUSHED-AHF)	29
Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis	28
Timing of Active Left Ventricular Unloading in Patients on Venoarterial Extracorporeal Membrane Oxygenation Therapy	28
Acute Myocarditis Associated With Desmosomal Gene Variants	27
Outpatient Management of Heart Failure During the COVID-19 Pandemic After Adoption of a Telehealth Model	27
High-Sensitivity Cardiac Troponin I Levels and Prediction of Heart Failure	26
Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure	26
Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes	26
Chloride in Heart Failure	25
Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure	25
Treatment of HF in an Era of Multiple Therapies	25
Predictive Value of Cardiopulmonary Exercise Testing Parameters in Ambulatory Advanced Heart Failure	25
Pragmatic Design of Randomized Clinical Trials for Heart Failure	25
Duration of Diabetes and Incident Heart Failure	23

Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction	23
Endpoints in Heart Failure Drug Development	23
Pulmonary Artery Catheter Use and Mortality in the Cardiac Intensive Care Unit	23
In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States	23
Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF	23
Clinical Characteristics and Trends in Heart Failure Hospitalizations	23
Prediction of Survival After Implantation of a Fully Magnetically Levitated Left Ventricular Assist Device	22
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype	22
Prognostic Implications of N-Terminal Pro–B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved	22
Impact of Temporary Percutaneous Mechanical Circulatory Support Before Transplantation in the 2018 Heart Allocation System	21
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF	21
Trends in Heart Failure–Related Mortality Among Older Adults in the United States From 1999-2019	21
Prevalence and Prognostic Significance of Mitral Regurgitation in Acute Decompensated Heart Failure	21
Potential Interactions When Prescribing SGLT2 Inhibitors and Intravenous Iron in Combination in Heart Failure	21
Prognostic Value of Peak Oxygen Uptake in Patients Supported With Left Ventricular Assist Devices (PRO-VAD)	21
Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF	21
Trends in HF Hospitalizations Among Young Adults in the United States From 2004 to 2018	21
Supranormal Left Ventricular Ejection Fraction, Stroke Volume, and Cardiovascular Risk	20
Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction	20
Associations Between Depressive Symptoms and HFpEF-Related Outcomes	20
Clinical Presentation and In-Hospital Trajectory of Heart Failure and Cardiogenic Shock	20
Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis	20
Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial	20
NT-proBNP for Risk Prediction in Heart Failure	19
Heart Failure Collaboratory Statement on Remote Monitoring and Social Distancing in the Landscape of COVID-19	19
Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome	19
Prognostic Value of Global Longitudinal Strain in Patients With Heart Failure With Improved Ejection Fraction	19
Hospitalization Patterns and Impact of a Magnetically-Levitated Left Ventricular Assist Device in the MOMENTUM 3 Trial	19
Home Health Care Use and Post-Discharge Outcomes After Heart Failure Hospitalizations	19
Beta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection Fraction	19
NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction	19
Sex-Specific Outcomes of Transcatheter Mitral-Valve Repair and Medical Therapy for Mitral Regurgitation in Heart Failure	18
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction	18
Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction	18
Insufficient Calorie Intake Worsens Post-Discharge Quality of Life and Increases Readmission Burden in Heart Failure	18
Chemoreflex and Baroreflex Sensitivity Hold a Strong Prognostic Value in Chronic Heart Failure	18
Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction	18
Utility of Biomarkers in Cardiac Amyloidosis	17
Effects of a Novel Nitroxyl Donor in Acute Heart Failure	17
Empagliflozin-Induced Changes in Epicardial Fat	17
Thromboembolism in Heart Failure Patients in Sinus Rhythm	17
A Standardized and Regionalized Network of Care for Cardiogenic Shock	17
Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes	16
Myocardial Infarction in Heart Failure With Preserved Ejection Fraction	16
Pathophysiologic Processes and Novel Biomarkers Associated With Congestion in Heart Failure	16
Association of Social Isolation and Loneliness With Incident Heart Failure in a Population-Based Cohort Study	15
Association Between Thigh Muscle Fat Infiltration and Incident Heart Failure	15
Estimating the Lifetime Benefits of Treatments for Heart Failure	15
Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute Heart Failure	15
REVeAL-HF	15
Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial	14
Health Status Predicts Short- and Long-Term Risk of Composite Clinical Outcomes in Acute Heart Failure	14
Mineralocorticoid Receptor Antagonist Improves Cardiac Structure in Type 2 Diabetes	14
Transvenous Right Greater Splanchnic Nerve Ablation in Heart Failure and Preserved Ejection Fraction	14
The Challenges of NT-proBNP Testing in HFpEF	14
Remote Speech Analysis in the Evaluation of Hospitalized Patients With Acute Decompensated Heart Failure	14
Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes	14
How to Manage Heart Failure With Preserved Ejection Fraction	13
Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy	13
Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan	13
Expenditure on Heart Failure in the United States	13
Forgone Medical Care Associated With Increased Health Care Costs Among the U.S. Heart Failure Population	13
Diagnostic and Prognostic Utilities of Insulin-Like Growth Factor Binding Protein-7 in Patients With Dyspnea	13
Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium	12
Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF	12
Spirituality in Patients With Heart Failure	12
Quadruple Therapy Is the New Standard of Care for HFrEF	12
The End of Endomyocardial Biopsy?	12
Cause of Death in Patients With Acute Heart Failure	12
Everolimus for the Prevention of Calcineurin-Inhibitor-Induced Left Ventricular Hypertrophy After Heart Transplantation (RADTAC Study)	12
Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction	12
Health Care Use Before First Heart Failure Hospitalization	11
Insights From HeartLogic Multisensor Monitoring During the COVID-19 Pandemic in New York City	11
Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction	11
Tolerability of Sacubitril/Valsartan in Patients With Advanced Heart Failure	11
Angiotensin-Neprilysin Inhibition in Black Americans	11
Cardiopulmonary Exercise Testing With Simultaneous Echocardiography	11
Cost-Effectiveness of Comprehensive Quadruple Therapy for Heart Failure With Reduced Ejection Fraction	11
Reclassification of Pre-Heart Failure Stages Using Cardiac Biomarkers	11
Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy	10

Hemodynamically-Guided Management of Heart Failure Across the Ejection Fraction Spectrum	10
Sequential Evaluation of NT-proBNP in Heart Failure	10
Response by Sex in Patient-Centered Outcomes With Baroreflex Activation Therapy in Systolic Heart Failure	10
Soluble Neprilysin and Corin Concentrations in Relation to Clinical Outcome in Chronic Heart Failure	10
Angiotensinogen	10
Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF	10
Assessment of HF Outcomes Using a Claims-Based Frailty Index	10
Relationship of Dapagliflozin With Serum Sodium	10
Acute Myocarditis With Ventricular Noncompaction in a COVID-19 Patient	10
Functional and Symptomatic Clinical Trial Endpoints	10
Happy Heart Syndrome	10
Psychiatric Comorbidity and Outcomes After Left Ventricular Assist Device Implantation for End-Stage Heart Failure	10
The Addition of a Defibrillator to Resynchronization Therapy Decreases Mortality in Patients With Nonischemic Cardiomyopathy	10
Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults	10
Cost and Value in Contemporary Heart Failure Clinical Guidance Documents	10
Early Blood Pressure Variables Associated With Improved Outcomes in VA-ECLS	9
Left Ventricular Assist Devices Versus Heart Transplantation for End Stage Heart Failure is a Misleading Equivalency	9
Depressive Symptoms and Incident Heart Failure Risk in the Southern Community Cohort Study	9
Prognostic Value of Time in Blood Pressure Target Range Among Patients With Heart Failure	9
Electronic Health Record-Based Deep Learning Prediction of Death or Severe Decompensation in Heart Failure Patients	9
The Maximally Tolerated Dose	9
Validation of the Kansas City Cardiomyopathy Questionnaire in Symptomatic Obstructive Hypertrophic Cardiomyopathy	9
Heart Failure Outcomes and Associated Factors Among Veterans With Human Immunodeficiency Virus Infection	9
Impact of the 2018 UNOS Heart Transplant Policy Changes on Patient Outcomes	9
Physical Activity, Subclinical Myocardial Injury, and Risk of Heart Failure Subtypes in Black Adults	9
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction	9
Postimplant Phosphodiesterase-5 Inhibitor Use in Centrifugal Flow Left Ventricular Assist Devices	9
Promoting Diversity in Clinical Trial Leadership: A Call to Action	8
Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes	8
Prognostic Importance of Health Status Versus Functional Status in Heart Failure and Secondary Mitral Regurgitation	8
Racial and Genetic Differences in Presentation of Transthyretin Amyloid Cardiomyopathy With Impaired Left Ventricular Function	8
Worsening Kidney Function Is the Major Mechanism of Heart Failure in Hypertension	8
Classifying Heart Failure in the 21st Century	8
Comparison of Demographic, Clinical, Biochemical, and Imaging Findings in Hypertrophic Cardiomyopathy Prognosis	8
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events	8
Guideline-Directed Medical Therapy Tolerability in Patients With Heart Failure and Mitral Regurgitation	8
Late Right Heart Failure After Left Ventricular Assist Device Implantation	8
Safety of Right and Left Ventricular Endomyocardial Biopsy in Heart Transplantation and Cardiomyopathy Patients	8
Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization	8
Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease	8
Heart Failure Collaboratory Statement on Clinical Trials in the Landscape of COVID-19	8
Beneficial Effects of Ketone Ester in Patients With Cardiogenic Shock	7
Contemporary Applications of Machine Learning for Device Therapy in Heart Failure	7
Approaches to Genetic Screening in Cardiomyopathies	7
Diabetes Mellitus, Race, and Effects of Omega-3 Fatty Acids on Incidence of Heart Failure Hospitalization	7
Percutaneous Mitral Valve Annuloplasty in Patients With Secondary Mitral Regurgitation and Severe Left Ventricular Enlargement	7
Management of Heart Failure–Related Cardiogenic Shock	7
Treatment Differences in Medical Therapy for Heart Failure With Reduced Ejection Fraction Between Sociodemographic Groups	7
Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction	7
Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure	7
Microbially Produced Imidazole Propionate Is Associated With Heart Failure and Mortality	7
Global Variations According to Sex in Patients Hospitalized for Heart Failure in the REPORT-HF Registry	7
Putting the “Optimal” in Optimal Medical Therapy	6
Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States	6
Retinal Microvasculature	6
Longer-Term Effects of Remote Patient Management Following Hospital Discharge After Acute Systolic Heart Failure	6
Cardiopulmonary Exercise Testing-Based Risk Stratification in the Modern Era of Advanced Heart Failure Management	6
Mineralocorticoid Receptor Antagonists and SGLT2 Inhibitor Therapy	6
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction	6
Clinical Course of Patients in Cardiogenic Shock Stratified by Phenotype	6
Blood Volume Redistribution in Chronic Heart Failure With Splanchnic Nerve Blockade	6
IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction	6
Impact of Diabetes on Outcomes After Transcatheter Mitral Valve Repair in Heart Failure	6
1 Year HIIT and Omega-3 Fatty Acids to Improve Cardiometabolic Risk in Stage-A Heart Failure	6
Periodontal Status, C-Reactive Protein, NT-proBNP, and Incident Heart Failure	6
Heart Rate as a Marker of Relapse During Withdrawal of Therapy in Recovered Dilated Cardiomyopathy	6
Race and Socioeconomic Bias in Pediatric Cardiac Transplantation	6
Female Reproductive Factors and Risk of New-Onset Heart Failure	6
How to Initiate and Uptitrate GDMT in Heart Failure	6
COVID-19 Fatigue	6
Life-Prolonging Benefits of LVAD Therapy in Advanced Heart Failure	5
Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF	5
Plasma Amyloid-β in Relation to Cardiac Function and Risk of Heart Failure in General Population	5
Hospital at Home as a Novel Care Strategy for Worsening Heart Failure	5
Impact of Geographic Region on the COMMANDER-HF Trial	5
Advanced Cardiovascular Imaging in Clinical Heart Failure	5
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy	5
Short-Term Lactate Kinetics in Patients With Cardiogenic Shock	5
No-Implant Interatrial Shunt for HFpEF	5
Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the Swedish HF Registry	5
Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy	5
Biomarkers of Congestion	5
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure	5
Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction	5
Patient Eligibility for Established and Novel Guideline-Directed Medical Therapies After Acute Heart Failure Hospitalization	5
Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure	5
Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score	5
Fibrosis Biomarkers Predict Cardiac Reverse Remodeling	4
Effect of Training on Vascular Function and Repair in Heart Failure With Preserved Ejection Fraction	4
CPET for Long COVID-19	4
Prognostic Value of Urinary and Plasma C-Type Natriuretic Peptide in Acute Decompensated Heart Failure	4
Exercise Blood Pressure in Heart Failure With Preserved and Reduced Ejection Fraction	4
Temporary Mechanical Circulatory Support as a Bridge to Transplant	4
Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart Failure	4
Risks of Depression and Suicide After Diagnosis With Heart Failure	4